Skip to content
PatentBrief
Get alertsTop ↑

How Continuous Glucose Monitors Get Accurate Readings

This patent describes a system for continuous glucose monitors (CGMs) that automatically adjusts sensor readings by comparing them to a more accurate reference and correcting for time delays.

ActiveExpires 2043Owned by DexcomInvented by Apurv U. Kamath, James Patrick Thrower, Victoria Carr-Brendel + 3 more

Original patent title: “Signal processing for continuous analyte sensors”

Plain-English explanation by SahiLast reviewed · November 7, 2026

This patent describes a system for continuous glucose monitors (CGMs) that automatically adjusts sensor readings by comparing them to a more accurate reference and correcting for time delays. Owned by Dexcom with 2 claims, and it is expected to expire in 2043.

Coverage

What does this patent actually cover?

This patent describes an analyte monitoring system, like a continuous glucose monitor, that makes its readings more accurate. It uses an "analyte sensor" to constantly collect data, which is called "sensor data." A "processor module" then takes this sensor data and also receives "reference data" from a more precise "reference analyte monitor," such as a finger-stick blood glucose meter. The clever part is that the processor figures out the "time lag" between when the sensor records a change and when the reference monitor would show it. Based on this time lag, it matches up the sensor data points with the reference data points. Finally, it uses these matched, more accurate reference readings to "calibrate" the sensor data, making the continuous readings much more reliable. An "output module" then shows this corrected information to the user, for example, displaying an adjusted glucose level on a smartphone app.

The gap

What does this patent NOT cover?

  • Does not cover systems that only use a single sensor without comparing its data to a separate, more accurate reference monitor.
  • Does not cover analyte monitoring systems that do not actively determine and compensate for a time lag between sensor and reference data.
  • Does not cover calibration methods that do not involve matching specific sensor data points with reference data points based on a determined time lag.
  • Does not cover systems that only display raw, uncalibrated sensor data without any processing or adjustment based on reference values.
  • Does not cover systems that use a reference monitor but do not use its data to calibrate the continuous sensor readings.

These exclusions are unique to PatentBrief — derived from the actual claim language, not patent-office boilerplate.

Key facts

Patent numberUS 20230293056
StatusActive
FieldBiotech & Medicine
AssigneeDexcom
InventorsApurv U. Kamath, James Patrick Thrower, Victoria Carr-Brendel and 3 others
Filed2023
Expires2043
Claims2
Times cited0
LitigationNone on record
Value · $26K–$84KMinimal

What made this novel

The truly clever part is the system's ability to dynamically determine the time lag between the continuous sensor's readings and a more accurate reference, then use that specific lag to precisely match and calibrate the sensor data. This ensures the continuous readings are not only adjusted but adjusted correctly for when the body's glucose levels actually changed.

The Patent Drawing

Representative patent drawing for Signal processing for continuous analyte sensors (US 20230293056)
Representative figure · US 20230293056All figures on Google Patents →
Signal processing for continuo…(Primary claim)biotechmedical devicessoftwareconsumer electronicstelecommunications

Schematic visualization of the patent's claim structure. Hand-drawn diagrams in progress for each landmark patent.

Where you've seen this

Real-world examples

01

Dexcom G6 continuous glucose monitor

02

Dexcom G7 continuous glucose monitor

03

Freestyle Libre continuous glucose monitor (certain models)

04

Other continuous glucose monitoring systems for diabetes management

Why it matters

The bigger picture

This technology is crucial for continuous glucose monitoring (CGM) devices, which are vital for managing diabetes. By automatically calibrating sensor data against more accurate reference data and accounting for time delays, it helps ensure that people with diabetes receive reliable, real-time glucose information. This accuracy is essential for making informed decisions about insulin dosage, diet, and activity, directly impacting health outcomes and quality of life.

Filed

March 24, 2023

Market context

Who's building on this

Companies in this space

Dexcom Inc., the assigneeassigneeThe entity that owns the patent — usually the inventor's employer or a company.Read more →, is a leading company in continuous glucose monitoring (CGM) technology and actively develops and refines these systems. Other major players in the CGM space, such as Abbott Laboratories and Medtronic, also invest heavily in similar signal processing and calibration techniques to improve the accuracy and reliability of their own devices.

Market impact

This type of signal processing has significantly advanced the continuous glucose monitoring market. It has enabled CGM devices to become more accurate and reliable, reducing the need for frequent finger-stick tests and making diabetes management much easier and safer for millions of users. The improved accuracy has also allowed for better integration with insulin pumps and automated insulin delivery systems, driving innovation in closed-loop diabetes management solutions.

Claim 1 — Plain English

What this patent covers

This patent describes an analyte monitoring system, like a continuous glucose monitor, that makes its readings more accurate. It uses an "analyte sensor" to constantly collect data, which is called "sensor data." A "processor module" then takes this sensor data and also receives "reference data" from a more precise "reference analyte monitor," such as a finger-stick blood glucose meter. The clever part is that the processor figures out the "time lag" between when the sensor records a change and when the reference monitor would show it. Based on this time lag, it matches up the sensor data points with the reference data points. Finally, it uses these matched, more accurate reference readings to "calibrate" the sensor data, making the continuous readings much more reliable. An "output module" then shows this corrected information to the user, for example, displaying an adjusted glucose level on a smartphone app.

The clever bit

The truly clever part is the system's ability to dynamically determine the time lag between the continuous sensor's readings and a more accurate reference, then use that specific lag to precisely match and calibrate the sensor data. This ensures the continuous readings are not only adjusted but adjusted correctly for when the body's glucose levels actually changed.

What it does not cover

  • Does not cover systems that only use a single sensor without comparing its data to a separate, more accurate reference monitor.
  • Does not cover analyte monitoring systems that do not actively determine and compensate for a time lag between sensor and reference data.
  • Does not cover calibration methods that do not involve matching specific sensor data points with reference data points based on a determined time lag.
  • Does not cover systems that only display raw, uncalibrated sensor data without any processing or adjustment based on reference values.
  • Does not cover systems that use a reference monitor but do not use its data to calibrate the continuous sensor readings.

Patent timeline

Filing

Application submitted to the patent office

Expiration

Patent enters public domain

PatentBrief Score

Impact Score

Limited data

Citation count

0/40

No citations yet

Claim breadth

1/20

Narrow claimsclaimsThe numbered statements at the end of a patent that legally define what the inventor owns.Read more →

Recency

0/20

Older than 20 years

Assignee scale

0/20

Independent or smaller assigneeassigneeThe entity that owns the patent — usually the inventor's employer or a company.Read more →

PatentBrief Impact Score — based on citation count, claim breadth, recency, and assignee scale. Not a legal assessment.

Heuristic Value Estimate

What this patent might be worth

Minimal

$26K – $84K

Midpoint $53K · 16.3 yr remaining · industry ×2.2

Adjust inputs →

Heuristic only — blends forward/backward citation counts, claim scope, time remaining, litigation history, and CPC-derived industry baseline. Real valuations need a professional appraisal.

Claim text not yet imported for this patent

The original legal language

Original claims

2 claims as filed with the patent office.

Concepts involved

ClaimPrior artNon-obviousnessNoveltySpecificationAssigneePatent term

Cite this patent

Kamath, A. U., Thrower, J. P., Carr-Brendel, V., Brauker, J. H., Goode, P., & Xavier, B. How Continuous Glucose Monitors Get Accurate Readings (U.S. Patent No. 20,230,293,056). U.S. Patent and Trademark Office. https://patentbrief.org/patent/us/20230293056/signal-processing-for-continuous-analyte-sensors

Auto-generated from the patent record. Double-check author order and the issue date against the official USPTO document before submitting.

Embed

Add this patent to your site

Drop this plain-English patent card into any blog post or article — free, no signup. It always links back to the full breakdown here.

<div data-patentlens-widget data-patent-number="US20230293056"></div>
<script src="https://patentbrief.org/embed.js" async></script>

Stay in the loop

Get a weekly digest of new patents.

One email per week. No spam. Unsubscribe anytime.

Keep exploring

Related patents you should know

US 4683195 · 1987

How to Make Billions of Copies of a DNA Segment

This patent describes the Polymerase Chain Reaction (PCR), a method to rapidly create many copies of a specific piece of DNA or RNA, enabling its detection and analysis.

Cetus Corp

US 8697359 · 2014

How to Edit Genes in Human Cells Using an Engineered CRISPR System

This patent describes an engineered CRISPR-Cas9 system for precisely cutting DNA in eukaryotic cells to change how genes work, opening the door for gene editing in complex organisms.

Massachusetts Institute of Technology

US 7657849 · 2010

How the iPhone's Slide-to-Unlock Gesture Works

Apple's 2010 patent describes unlocking a device by dragging a specific graphical image across the touchscreen along a predefined path, a gesture that became iconic with the original iPhone.

Apple Inc

US 4733665 · 1988

How Doctors Implant a Permanent Stent Using a Balloon

This patent describes the method for placing a permanent, expandable wire mesh tube inside a blood vessel or other body tube using a balloon-tipped catheter to widen it and keep it open.

Expandable Grafts Partnership

US 4965188 · 1990

How to Make Many Copies of a DNA Piece with Heat

This patent describes the Polymerase Chain Reaction (PCR) method, a technique to make millions of copies of a specific DNA segment using a heat-resistant enzyme and repeated temperature changes.

Cetus Corp

US 4235871 · 1980

How to Encapsulate Active Materials in Lipid Bubbles Efficiently

This patent describes a method for trapping biologically active substances inside tiny, multi-layered fat bubbles called liposomes, using a specific water-in-oil emulsion and gel-forming process to improve how much material gets captured.

Individual

Semantically similar

You might also find these interesting

SEARCH ALL

More to explore

More in Biotech & Medicine

Browse all Biotech & Medicine

New to patents?

What is a patent?How to read a patentAnatomy of a claimHow strong is this patent?What the citations meanWhat it doesn't coverBiotech PatentsPatent glossary
Explore the landscape:biotech patents →medical devices patents →software patents →

Common Questions

Frequently Asked Questions

What does How Continuous Glucose Monitors Get Accurate Readings cover?

This patent describes a system for continuous glucose monitors (CGMs) that automatically adjusts sensor readings by comparing them to a more accurate reference and correcting for time delays.

Who owns patent US 20230293056?

This patent is owned by Dexcom.

When does this patent expire?

This patent is expected to expire on March 24, 2043, when the invention enters the public domain.

What problem does this patent solve?

This technology is crucial for continuous glucose monitoring (CGM) devices, which are vital for managing diabetes. By automatically calibrating sensor data against more accurate reference data and accounting for time delays, it helps ensure that people with diabetes receive reliable, real-time glucose information. This accuracy is essential for making informed decisions about insulin dosage, diet, and activity, directly impacting health outcomes and quality of life.

What does this patent NOT cover?

Does not cover systems that only use a single sensor without comparing its data to a separate, more accurate reference monitor.

Same assignee

More from Dexcom

View all →
US 11432772·2022

Smartly Fixing Noisy Glucose Sensor Readings

US 11382539·2022

A Catheter That Measures Glucose While Delivering Medication

US 10052055·2018

How an Implanted Sensor Checks Its Own Accuracy Over Time

US 9282925·2016

How Glucose Sensors Check Their Own Reliability for Insulin Pumps

Patent monitoring

Get notified when Dexcom files a new patent

Get notified when this company files a new patent. Weekly digest · Confirm via email · Unsubscribe anytime.

Last reviewed: November 7, 2026 · PatentBrief is not a law firm and this is not legal advice.